Effects of Carvedilol on Heart Rate Dynamics in Patients with Congestive Heart Failure
- 1 April 2002
- journal article
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 7 (2) , 133-138
- https://doi.org/10.1111/j.1542-474x.2002.tb00154.x
Abstract
Patients with congestive heart failure (CHF) have alterations in the traditional and nonlinear indices of heart rate (HR) dynamics, which have been associated with an increased risk of mortality. This study was designed to test the effects of carvedilol, a nonselective beta-blocker with alpha-1 blocking properties, on HR dynamics in patients with CHF. We studied 15 patients with CHF secondary to ischemic or idiopathic cardiomyopathy who met the following inclusion criteria: NYHA functional class II-III, optimal conventional medical therapy, normal sinus rhythm, left ventricular ejection fraction (LVEF) of < 40%, and resting systolic blood pressure greater than 100 mmHg. The 6-minute corridor walk test, estimation of LVEF, and 24-hour Holter recording were performed at baseline and after 12 weeks of therapy with carvedilol. Traditional time and frequency domain measures and short-term fractal scaling exponent of HR dynamics were analyzed. After 12 weeks of therapy with carvedilol, the mean LVEF improved significantly (from 0.27 +/- 0.08 to 0.38 +/- 0.08, P < 0.001). The average HR decreased significantly (from 86 +/- 11 to 70 +/- 8 beats/min, P < 0.001). The mean distance traveled in the 6-minute walk test increased significantly (from 177 +/- 44 to 273 +/- 55 m, P < 0.01). The frequency-domain indices (HF and LF), the time domain indices (rMSSD and PNN5 ), and the short-term fractal scaling exponent increased significantly. The scaling exponent increased particularly among the patients with the lowest initial values (< 1.0), and the change in the fractal scaling exponent correlated with the change in ejection fraction (r = 0.63, P < 0.01). Carvedilol improves time and frequency domain indices of HR variability and corrects the altered scaling properties of HR dynamics in patients with CHF. It also improves LVEF and functional capacity. These specific changes in HR behavior caused by carvedilol treatment may reflect the normalization of impaired cardiovascular neural regulation of patients with CHF.Keywords
This publication has 27 references indexed in Scilit:
- Is abnormal heart rate variability a specific feature of congestive heart failure?The American Journal of Cardiology, 2001
- Fractal analysis and time- and frequency-domain measures of heart rate variability as predictors of mortality in patients with heart failureThe American Journal of Cardiology, 2001
- Beta-blockade in heart failure: A comparison of carvedilol with metoprololJournal of the American College of Cardiology, 1999
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Influence of metoprolol on heart rate variability in survivors of remote myocardial infarctionThe American Journal of Cardiology, 1996
- Effects of enalapril on heart rate variability in patients with congestive heart failureThe American Journal of Cardiology, 1995
- Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarctionThe American Journal of Cardiology, 1994
- Effect of Beta-blockade on heart rate variability in patients with coronary artery diseaseJournal of the American College of Cardiology, 1994
- Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathyJournal of the American College of Cardiology, 1993
- Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1992